12:00 AM
 | 
Feb 06, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Avastin bevacizumab: Phase III data

Researchers at the German Breast Group and colleagues reported data from 1,948 previously untreated HER2-negative breast cancer patients in the open-label, German Phase III GeparQuinto showing that a significantly greater proportion of patients receiving Avastin plus chemotherapy (epirubicin plus cyclophosphamide and docetaxel) achieved a pCR, the primary endpoint, vs. chemotherapy alone (18.4% vs. 14.9%, p=0.04). Furthermore, a subgroup analysis showed that pCRs were primarily restricted to patients with hormone-receptor-negative tumors. Specifically, in...

Read the full 337 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >